Atrium Therapeutics, Inc. (RNA) Stock Grade

About Atrium Therapeutics, Inc.'s fundamentals

Atrium Therapeutics is a biotechnology company with a market capitalization of $252.4 million that is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -411.9%. The company generated no year-over-year revenue growth, indicating flat sales performance. As a pre-revenue or early-stage biotech company, it does not pay dividends and typical profitability metrics like P/E ratio and return on equity are not applicable.